Special Issue "Sex Hormone Receptor Signals in Human Malignancies 2.0"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 2211
Interests: nuclear hormone receptors; androgen receptor; glucocorticoid receptor; antiandrogens; glucocorticoids; urothelial cancer; prostate cancer; genitourinary pathology
Special Issues, Collections and Topics in MDPI journals
Special Issue in Cancers: Hormone Receptors in Genitourinary Tumors
Topical Collection in Cells: Functions of Nuclear Receptors
Topical Collection in Cells: Feature Papers in Cell Nuclei: Function, Transport and Receptors
Special Issue in Cells: 10th Anniversary of Cells—Advances in Cell Nuclei: Function, Transport and Receptors
Special Issue in Cells: The Role of Androgen Receptor in Prostate Cancer—Revisited
This Special Issue is the second volume of our previous Special Issue “Sex Hormone Receptor Signals in Human Malignancies”. Sex steroids, including androgens, estrogens, and progestogens, are known to have widespread physiological actions beyond the reproductive system via binding to the sex hormone receptors, members of the nuclear receptor superfamily that function as ligand-inducible transcription factors. Meanwhile, the roles of androgen receptor and estrogen/progesterone receptors have been widely studied in prostate and breast cancers, respectively. However, emerging evidence implies that sex hormone receptor signals play a role in the development and progression of various other types of malignancies, although their exact functions are not fully characterized. These malignancies include, but are not limited to, endometrial cancer, ovarian cancer, urothelial tumor of the bladder or upper urinary tract, liver cancer, lung cancer, and gastrointestinal cancer. Thus, the aim of this Special Issue is to provide an overview of current preclinical and clinical findings indicating the involvement of sex hormone receptor signals in human malignancies that have not traditionally been considered as endocrine neoplasms. Original research or review articles on androgen/estrogen/progesterone receptor signaling in prostate or breast cancer would also be most welcome.
Prof. Dr. Hiroshi Miyamoto
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- androgen receptor
- estrogen receptor
- progesterone receptor
- prostate cancer
- breast cancer
- female reproductive system cancer
- urothelial cancer
- liver cancer
- lung cancer
- gastrointestinal cancer